News
MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...
Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.
Stockhead on MSN13h
Neurizon’s ALS drug shows safety and extended survival in open-label extension study
Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...
Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
TipRanks on MSN4h
NeuroSense Reports Long-Term Safety of PrimeC in ALS Study
The latest update is out from Neurosense Therapeutics Ltd. ( ($NRSN) ). As of August 20, 2025, NeuroSense Therapeutics Ltd. reported that ...
• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback